



July 8, 2026

STATEMENT FROM JAGUAR GENE THERAPY

We are pleased to share some updates with the Phelan-McDermid syndrome community as part of our commitment to provide timely and transparent information as the JAG201 program continues to progress. We encourage you to read through the following news as well as the updated FAQ.

- The first-in-human clinical trial evaluating the safety, tolerability and clinical activity of JAG201 continues to proceed as planned and on time.
- Seven pediatric patients have now been dosed with JAG201 in the trial. At this time, no serious adverse events (SAE) related to treatment have been reported. We look forward to providing additional updates as the trial progresses.
- Jaguar and our partners have recently launched a developmental milestone study for caregivers that focuses on better understanding how developmental milestones, or skills, develop over time in individuals living with Phelan-McDermid syndrome. We are actively seeking caregiver participants for this study. Jaguar is working to explore how the data from this study could inform and accelerate the drug development process for JAG201.
 - Please note inclusion/exclusion criteria for the study have been updated since the community webinar held in April.
- If you or a caregiver you know may be interested in participating in the developmental milestone study, visit www.pmscaregiverstudy.com to learn more.

We continue to extend our gratitude to CureSHANK and the Phelan-McDermid Syndrome Foundation for their ongoing partnership. We would also like to thank those caregivers who have already enrolled in the developmental milestone study, as we know your time and input are incredibly valuable.